Biogen, Atlas Venture latest effort to develop treatment for ataxia
Ataxion has raised $17 million in a Series A round to develop treatments for inherited versions of the disease from Atlas Venture and Biogen.
It reflects a broader life sciences industry trend of developing treatments for orphan diseases because there’s a higher barrier to entry and it allows companies to keep exclusivity for longer periods of time than conditions with larger patient populations.
Tuesday, March 18, 2014
Subscribe to:
Posts (Atom)
